EE200300467A - Liposoomide suunamine maatriksi metalloproteinaaside inhibiitorite abil - Google Patents

Liposoomide suunamine maatriksi metalloproteinaaside inhibiitorite abil

Info

Publication number
EE200300467A
EE200300467A EEP200300467A EEP200300467A EE200300467A EE 200300467 A EE200300467 A EE 200300467A EE P200300467 A EEP200300467 A EE P200300467A EE P200300467 A EEP200300467 A EE P200300467A EE 200300467 A EE200300467 A EE 200300467A
Authority
EE
Estonia
Prior art keywords
liposomes
matrix metalloproteinase
metalloproteinase inhibitors
tumor cells
cells
Prior art date
Application number
EEP200300467A
Other languages
English (en)
Estonian (et)
Inventor
Penate Medina Oula
Koivunen Erkki
Kinnunen Paavo
Original Assignee
Ctt Cancer Targeting Technologies Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ctt Cancer Targeting Technologies Oy filed Critical Ctt Cancer Targeting Technologies Oy
Publication of EE200300467A publication Critical patent/EE200300467A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200300467A 2001-03-26 2002-03-26 Liposoomide suunamine maatriksi metalloproteinaaside inhibiitorite abil EE200300467A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20010620A FI113840B (fi) 2001-03-26 2001-03-26 Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa
PCT/FI2002/000252 WO2002076491A1 (en) 2001-03-26 2002-03-26 Liposome targeting of matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
EE200300467A true EE200300467A (et) 2003-12-15

Family

ID=8560842

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300467A EE200300467A (et) 2001-03-26 2002-03-26 Liposoomide suunamine maatriksi metalloproteinaaside inhibiitorite abil

Country Status (23)

Country Link
US (2) US20040213833A1 (xx)
EP (1) EP1372694B1 (xx)
JP (1) JP2004529127A (xx)
KR (1) KR20040000414A (xx)
CN (1) CN1250279C (xx)
AT (1) ATE331526T1 (xx)
BR (1) BR0208681A (xx)
CA (1) CA2441227A1 (xx)
CZ (1) CZ20032805A3 (xx)
DE (1) DE60212814T2 (xx)
DK (1) DK1372694T3 (xx)
EE (1) EE200300467A (xx)
ES (1) ES2266458T3 (xx)
FI (1) FI113840B (xx)
HU (1) HUP0303649A3 (xx)
IL (1) IL158114A0 (xx)
NO (1) NO20034280L (xx)
NZ (1) NZ528043A (xx)
PL (1) PL365248A1 (xx)
RU (1) RU2003131332A (xx)
SK (1) SK12982003A3 (xx)
WO (1) WO2002076491A1 (xx)
YU (1) YU74703A (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
IL152609A0 (en) * 2002-11-03 2003-06-24 Hapto Biotech Inc Liposomal compositions comprising haptotactic peptides and uses thereof
CN1314704C (zh) * 2002-11-20 2007-05-09 中国人民解放军军事医学科学院放射与辐射医学研究所 基质金属蛋白酶2的小肽抑制剂
AU2004207824A1 (en) * 2003-01-24 2004-08-12 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
FI115035B (fi) * 2003-05-02 2005-02-28 Ctt Cancer Targeting Tech Oy In vivo -kuvantaminen käyttäen peptidijohdannaisia
FI20031528A0 (fi) * 2003-10-17 2003-10-17 Ctt Cancer Targeting Tech Oy Terapeuttinen liposomikoostumus ja menetelmä sen valmistamiseksi
FI20040572A0 (fi) * 2004-04-23 2004-04-23 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasin aktiviteetin inhibiittorit
FI20040682A0 (fi) * 2004-05-14 2004-05-14 Ctt Cancer Targeting Tech Oy Tuumorien ja mestastaasien kuvantaminen käyttäen gelatinaasiin targetoituvaa peptidiä
FR2870741B1 (fr) 2004-05-25 2008-03-14 Coletica Sa Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant.
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP2009542691A (ja) * 2006-07-06 2009-12-03 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 血管造影用の様々なサイズの多染性粒子
CN102114000B (zh) * 2009-12-31 2013-08-21 复旦大学 一种载药的共输送脂质纳米递药系统
US8871189B2 (en) * 2011-11-30 2014-10-28 Mallinckrodt Llc MMP-targeted therapeutic and/or diagnostic nanocarriers
JP2020500020A (ja) 2016-11-14 2020-01-09 ノバルティス アーゲー 融合誘導性タンパク質ｍｉｎｉｏｎに関連する組成物、方法、および治療上の使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158760A (en) * 1990-05-30 1992-10-27 Board Of Regents, The University Of Texas System 99m TC labeled liposomes
US6087325A (en) * 1996-10-15 2000-07-11 The Liposome Company, Inc. Peptide-lipid conjugates
FI980604A0 (fi) * 1998-03-18 1998-03-18 Univ Helsinki Licensing Nya matrismetalloproteinasinhibitorer och -regulatorer

Also Published As

Publication number Publication date
YU74703A (sh) 2006-05-25
CN1531439A (zh) 2004-09-22
NZ528043A (en) 2005-08-26
KR20040000414A (ko) 2004-01-03
DE60212814D1 (de) 2006-08-10
BR0208681A (pt) 2004-03-30
FI20010620A0 (fi) 2001-03-26
FI20010620A (fi) 2002-09-27
HUP0303649A2 (hu) 2004-01-28
DK1372694T3 (da) 2006-10-30
CA2441227A1 (en) 2002-10-03
NO20034280D0 (no) 2003-09-25
CN1250279C (zh) 2006-04-12
ES2266458T3 (es) 2007-03-01
FI113840B (fi) 2004-06-30
EP1372694A1 (en) 2004-01-02
PL365248A1 (en) 2004-12-27
EP1372694B1 (en) 2006-06-28
RU2003131332A (ru) 2005-04-10
US20040213833A1 (en) 2004-10-28
ATE331526T1 (de) 2006-07-15
WO2002076491A1 (en) 2002-10-03
NO20034280L (no) 2003-11-25
HUP0303649A3 (en) 2005-12-28
US20050271588A1 (en) 2005-12-08
CZ20032805A3 (cs) 2004-06-16
DE60212814T2 (de) 2007-02-08
IL158114A0 (en) 2004-03-28
SK12982003A3 (sk) 2004-08-03
JP2004529127A (ja) 2004-09-24

Similar Documents

Publication Publication Date Title
EE200300467A (et) Liposoomide suunamine maatriksi metalloproteinaaside inhibiitorite abil
WO2003002595A3 (en) Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
EA200800268A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
EA200700686A1 (ru) Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
CY1110329T1 (el) Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743
HUP0402656A2 (hu) Sejtterápiás eljárás tumorok kezelésére
EA200300934A1 (ru) Агенты и способы, предназначенные для лечения опухолевых заболеваний
AU2001272017A1 (en) Targeted combination immunotherapy of cancer and infectious diseases
ATE313334T1 (de) Behandlung von tumoren mit photodynamischer therapie
WO2003106640A3 (en) CELL TARGETING METHODS AND COMPOSITIONS
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
DE60331827D1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
SE0100684D0 (sv) New subject-matter
WO2002074756A3 (de) Urokinase-inhibitoren
HUP0301276A2 (hu) Kombinációs terápia ösztrogénérzékeny betegségek kezelésére
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
WO2004052282A3 (en) Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents
AU2003236701A8 (en) Guanidino phenylalanin compounds used as urokinase inhibitors
GB2431656A (en) HAI-1 and HAI-2 in cancer therapy
DE69938501D1 (de) Verwendung von prohibitin-rns in krebsbehandlung
BR0308976A (pt) Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia
WO2006020557A3 (en) Methods of using or identifying agents that inhibit cancer growth
DE50301954D1 (de) Liposomale formulierungen von phenylalanin-derivaten